Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PridCor Therapeutics advances its SHIELD Long COVID study with a peer-reviewed publication and FDA confirmation of IND exemption.
-
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
-
SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- PolarityBio©, a clinical-stage biotechnology company focused on addressing unmet needs in wound healing through innovation in autologous...
-
Our findings demonstrate that PRP exerts multifaceted effects specifically over the cancer associated fibroblasts (CAFs) population and tumor cells.
-
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
-
NeuExcell’s NXL-004, first in situ conversion gene therapy, shows promising safety and efficacy in 11 GBM patients at ESMO Asia 2025
-
• Ameluz® and RhodoLED® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera Inc.• Assignment to Biofrontera Inc. of 11 granted...
-
Avacta announced compelling new data in patients with salivary gland cancer enrolled in the ongoing Phase 1b trial of faridoxorubicin (AVA6000)
-
IND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents...
-
STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...